Estimaciones de analistas de Wall Street para BioVie Inc. (BIVI): precio objetivo de consenso, recomendaciones de compra/mantener/venta y previsiones de ingresos, BPA y EBITDA para los próximos ejercicios.
Consenso de analistas
| Compra fuerte | 0 |
| Compra | 5 |
| Mantener | 0 |
| Venta | 0 |
| Venta fuerte | 0 |
| Analistas totales | 5 |
| Calificación media (1-5) | 1.00 |
Sorpresas de Resultados Recientes
| Fecha | BPA Real | BPA Estimado | vs Est. |
|---|---|---|---|
| 2026-11-09 | |||
| 2026-08-12 | $-0.70 | $-0.52 | -34.6% |
| 2026-05-11 | $-0.70 | $-0.73 | +4.1% |
| 2026-02-10 | $-0.77 | $-0.81 | +4.9% |
| 2025-11-10 | $-0.98 | $-0.79 | -24.1% |
| 2025-08-15 | $-1.82 | $-1.82 | +0.0% |
| 2025-05-12 | $-1.50 | $-3.20 | +53.1% |
| 2025-02-11 | $-4.60 | $-16.00 | +71.2% |
Ratios de valoración
| Precio / Valor contable | 1.29 |
| EV / EBITDA | -0.31 |
| Rentabilidad por dividendo | 0.00% |
Cuenta de Resultados (10 años)
| Año | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ingresos | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Coste de Ventas | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $229377 | 0 |
| Beneficio Bruto | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -$229377 | 0 |
| I+D | $466354 | $370853 | $1.0M | $1.2M | $133.2M | $17.3M | $33.3M | $23.1M | $9.3M | $14.0M |
| Generales y Administrativos | $857883 | $1.8M | $1.3M | 0 | 0 | 0 | $11.6M | 0 | $8.6M | $8.5M |
| Gastos Operativos | $1.6M | $2.4M | $2.5M | $2.7M | $138.1M | $27.3M | $45.1M | $32.2M | $17.8M | $22.7M |
| Beneficio Operativo | -$1.6M | -$2.4M | -$2.5M | -$2.7M | -$138.1M | -$27.3M | -$45.1M | -$32.2M | -$18.1M | -$22.7M |
| EBITDA | -$1.3M | -$2.1M | -$2.3M | -$2.5M | -$129.5M | -$23.7M | -$45.7M | -$29.0M | -$17.0M | -$21.9M |
| Gastos por Intereses | 0 | $40960 | $273 | $4.8M | $559455 | $2.2M | $4.3M | $2.9M | $332720 | $17901 |
| Beneficio Antes de Impuestos | -$1.3M | -$2.4M | -$2.4M | -$16.7M | -$130.2M | -$26.1M | -$50.3M | -$32.1M | -$17.5M | -$22.1M |
| Impuestos | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Beneficio Neto | -$1.3M | -$2.4M | -$2.4M | -$16.7M | -$130.2M | -$26.1M | -$50.3M | -$32.1M | -$17.5M | -$22.1M |
| BPA | $-186.10 | $-317.70 | $-98.20 | $-685.20 | $-1482.30 | $-106.00 | $-154.70 | $-73.05 | $-12.12 | $-3.05 |
| BPA Diluido | $-186.10 | $-317.70 | $-98.20 | $-685.20 | $-1482.30 | $-106.00 | $-154.70 | $-73.05 | $-12.12 | $-3.05 |
| Acciones en Circulación (Diluidas) | $7151 | $7661 | $25396 | $49295 | $124031 | $246625 | $324834 | $451853 | $1.5M | $7.2M |
Precio
| Precio | $1.72 |
| Capitalización | $13M |
| Bolsa | NASDAQ |
| País | US |
Empresas relacionadas: ARTL · CANF · CERO · ELAB · GLMD · INM · KZIA
Explorar sector: Healthcare · Biotechnology
Más secciones de BIVI: Resumen · Financieros · Valoración · Estadísticas · Técnico · Propiedad · Noticias · Eventos
Descubre más: Radar — señales de acciones infravaloradas · Academia de Inversión — aprende a analizar acciones